GlassScriptPhysician profile
Anthony P Corcoran
NPI 1235321910
$1,349.27
in general payments reported to CMS, 2019-2025
11 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.60 · 2022: $38.63 · 2023: $254 · 2024: $435 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $177.68 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $158.72 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $139.57 | 2024-2025 | |
| Lilly USA, LLC | $126.53 | 2021-2025 | Zepbound, Mounjaro, Emgality |
| Merck Sharp & Dohme LLC | $93.04 | 2021-2025 | Capvaxive |
| Pfizer INC. | $67.24 | 2024-2025 | |
| Amgen INC. | $60.99 | 2023-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.29 | 2025 | Jardiance |
| Astellas Pharma US INC | $36.53 | 2024-2025 | Veozah |
| Medtronic, INC. | $16.35 | 2023 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.